TFC Therapeutics is a biotechnology company developing novel biologics to target and eliminate key drivers of cancer. The Company's emerging technology platform is focused on targeting and eliminating Tumor Macrophage Hybrid (TMH) cells. TMH cells are implicated in metastasis, treatment resistance, and relapse. TFC was founded by scientists and executives with deep cancer biology expertise and a commitment to delivering benefit to patients based on rigorous pursuit of novel approaches to cancer therapy. TFC is headquartered in New York, NY and secured initial funding in August 2023.
